https://www.selleckchem.com/pr....oducts/trastuzumab-d
0001), allodynia (OR 1.43; 95% CI 1.10-1.85, p = 0.0071) and unilateral cranial autonomic symptoms (OR 1.31; 95% CI 1.01-1.68, p = 0.045), but used less preventative treatments (OR 0.74; 95% CI 0.57-0.98, p = 0.033) than patients without dopaminergic symptoms. Conclusions Migraine patients with dopaminergic symptoms are characterized by a full-blown, more disabling migraine. Dopaminergic system modulation should be carefully considered in individuals with migraine with dopaminergic symptoms for both acute and preventative
Like
Comment
Share
